ANDAORAL-28TABLET
Approved
Oct 2007
Lifecycle
Post-LOE
Competitive Pressure
30/100
Data completeness
4/8 — Partial
TRI-LEGEST FE (norethindrone acetate and ethinyl estradiol) by Teva is estrogen receptor agonists [moa]. Approved for estrogen [epc]. First approved in 2007.
Drug data last refreshed 19h ago
$0.0BPart D
Mechanism of Action
Estrogen Receptor Agonists
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Company
Teva
Israel - Petach Tikva
Worked on TRI-LEGEST FE at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.